{"filing":{"accession_number":"0001689548-26-000066","cik":"0001689548","ticker":"PRAX","company_name":"Praxis Precision Medicines, Inc.","form":"8-K","filing_date":"2026-06-22","report_date":null,"primary_document":"prax-20260622.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1689548/000168954826000066/prax-20260622.htm"},"events":[{"id":12830,"run_id":11386,"accession_number":"0001689548-26-000066","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Praxis announced FDA Breakthrough Therapy Designation for elsunersen (PRAX-222) for SCN2A-DEE, supported by positive Phase 1/2 trial results. This is a material regulatory milestone that accelerates development and review timelines for a lead candidate, directly affecting the company's clinical and commercial prospects. While not fitting a specific named category, this is clearly an operational/strategic event material to investors assessing the registrant's pipeline progress.","company_name":"Praxis Precision Medicines, Inc.","ticker":"PRAX","filing_date":"2026-06-22","form":"8-K","submitted_at":null,"items":[{"id":9795,"accession_number":"0001689548-26-000066","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Praxis announced FDA Breakthrough Therapy Designation for elsunersen (PRAX-222) for SCN2A-DEE, supported by positive Phase 1/2 trial results. This is a material regulatory milestone that accelerates development and review timelines for a lead candidate, directly affecting the company's clinical and commercial prospects. While not fitting a specific named category, this is clearly an operational/strategic event material to investors assessing the registrant's pipeline progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T21:31:56.156736+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":9795,"accession_number":"0001689548-26-000066","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Praxis announced FDA Breakthrough Therapy Designation for elsunersen (PRAX-222) for SCN2A-DEE, supported by positive Phase 1/2 trial results. This is a material regulatory milestone that accelerates development and review timelines for a lead candidate, directly affecting the company's clinical and commercial prospects. While not fitting a specific named category, this is clearly an operational/strategic event material to investors assessing the registrant's pipeline progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T21:31:56.156736+00:00","company_name":"Praxis Precision Medicines, Inc.","ticker":"PRAX","filing_date":"2026-06-22"}]}